• PCSK9 and Praluent®

    SPECIFIC CHARACTERISTICS OF PRALUENT®

    Find out more

    Praluent® patients

    POST-ACS PATIENTS ARE AT HIGH RISK FOR RECURRENT CV EVENTS2

    Find out more

    ODYSSEY OUTCOMES

    PRALUENT® RESULTS FROM THE ODYSSEY OUTCOMES TRIAL

    Find out more

    NEW 4-WEEKLY (MONTHLY) SINGLE INJECTION
    AN OPTION FOR YOUR PATIENTS WHO REQUIRE AN LDL-C REDUCTION >60%1


    FIND OUT MORE

    The usual starting dose for Praluent is 75 mg administered subcutaneously once every 2 weeks. Patients suitable for Praluent, who require larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly)1

    Keep updated about educational materials for you and your patients

    REQUEST A CALL KEEP IN TOUCH WITH SANOFI

    In patients with a prior CV event who need further LDL-C lowering,

    PRALUENT® SIGNIFICANTLY REDUCED THE RISK OF MACE IN PATIENTS ALREADY ON HIGH-INTENSITY STATINS2

    Discover the results of the ODYSSEY OUTCOMES trial.

    Learn more about the ODYSSEY OUTCOMES study design View safety results from ODYSSEY OUTCOMES

    View the full study design

    Study design: ODYSSEY OUTCOMES was a randomized, double-blind, placebo-controlled phase 3 study. Patients with a recent MI or unstable angina, and on high-intensity statin (40 or 80 mg atorvastatin or 20 or 40 mg rosuvastatin, or maximally tolerated dose of one of these agents) +/- other lipid-lowering therapy but not at predefined target LDL-C were enrolled.2

    Study design: ODYSSEY OUTCOMES was a randomized, double-blind, placebo-controlled phase 3 study. Patients with a recent MI or unstable angina, and on high-intensity statin (40 or 80 mg atorvastatin or 20 or 40 mg rosuvastatin, or maximally tolerated dose of one of these agents) +/- other lipid-lowering therapy but not at predefined target LDL-C were enrolled.2

    PRALUENT® APPROVED TO REDUCE CV RISK

    Praluent (alirocumab) is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:

    • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,
    • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated1
    SEE FULL INDICATION

    Footnotes & references

    *A CV event defined as a part of a composite in ODYSSEY OUTCOMES clinical trial is coronary heart disease death, non-fatal myocardial infarction, fatal or non-fatal ischaemic stroke, or unstable angina requiring hospitalisation2

    ACS=acute coronary syndrome; CHD=coronary heart disease; CI=confidence interval; CV=cardiovascular; HR=hazard ratio; LDL-C=low-density lipoprotein cholesterol; MACE=major adverse cardiac events (primary composite endpoint of CHD death, nonfatal myocardial infarction, fatal and nonfatal ischaemic stroke, or unstable angina requiring hospitalization); MI=myocardial infarction; PCSK9i=proprotein convertase subtilisin/kexin type 9 inhibitor; RRR=relative risk reduction.

    1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed August 2021.
    2. Schwartz G, et al. N Engl J Med 2018;379(22):2097–2107.
    3. Schwartz G, et al. N Engl J Med 2018;379(22):2097–2107. Supplementary Appendix.